A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix

Cancer

Volumn 82, Issue 2, 1998, Pages 328-333

  Irvin, William P ^a   Price, Fredric V ^b   Bailey, Howard ^c   Gelder, Mark ^d   Rosenbluth, Richard ^e   Durivage, Henry J ^f   Potkul, Ronald K ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^f Princeton   (United States)

Author keywords

Cervical carcinoma; Chemotherapy; CPT 11; Irinotecan

Indexed keywords

ATROPINE; CISPLATIN; IRINOTECAN; LOPERAMIDE; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA; VOMITING;

EID: 0031976028     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19980115)82:2<334::aid-cncr13>3.0.co;2-%23     Document Type: Article

References (22)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;(46)1:5-27.
2. Bonomi P, Blessing JA, Stehrman FB. Randomized trial of three cisplatin dose schedules in SCCA of the cervix. A Gynecologic Oncology Group Study. J Clin Oncol 1985;3:1079-85.
3. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents: the isolation and structures of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966;88:3888-90.
4. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972;56:96-101.
5. Gottleib JA, Luce JK. Treatment of malignant melanoma with camptothecin (NSC-100880) Cancer Chemother Rep 1972; 56:103-5.
6. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972;56:515-21.
7. Matsuzaki T, Yokokura T, Mutai M, Tsuruo T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 1988;21(4):308-12.
8. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharamacol 1988;21(1):71-4.
9. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, et al. Antitumor activity of 7-ethyl-10-[4- (1-peperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-7.
10. Masuda N, Fukuoka M, Kasunoki Y, Matsui K, Takifuji N, Kudoh S, et al. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-9.
11. Takeuchi S, Noda K, Yakushiji M. Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol 1992;11:224.
12. Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, et al. A late phase II trial of a potent topoisomerase I inhibitor, CPT-11, in malignant lymphoma. Proc Am Soc Clin Oncol 1992;11:316.
13. Taguchi T. Clinical studies of CPT-11 in Japan [abstract 30]. Fourth Conference on DNA Topoisomerases in Therapy, New York, New York, October 26-29, 1992:31.
14. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
15. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.
16. Giovanella BC, Stehlin JS, Wall ME, Mansukh CW, Nicholas AW, Liu LF, et al. DNA topoisomerase I- targeted chemotherapy of human colon cancer xenografts. Science 1989;246:1046-8.
17. Schneider E, Hsiang YH, Liu LF. DNA topoisomerases as anticancer drug targets. Adv Pharmacol 1990;21:149-83.
18. Hsiang YH, Wu HY, Liu LF. Topoisomerases: novel therapeutic targets in cancer chemotherapy. Biochem Pharmacol 1988;37(9):1801-2.
19. Rothenberg ML, Kuhn JG, Burris HA, Nelson J, Eekardt JR, Tristan-Morales M, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993;11(11):2194-204.
20. Verschraegen CF, Levy T, Llerena E, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;15(2):625-31.
21. Wang Z, Sinha BK. Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo. Mol Pharmacol 1996;49(2):269-75.
22. Kobayashi I, Ohwada S, Maemura M. Interferon-alpha potentiates the antiproliferative activity of CPT-11 against human colon cancer xenografts in nude mice. Anticancer Res 1996;16(5A):2677-80.